AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure Blog Post

AELIX Therapeutics, a clinical-stage biotechnology company based in the Barcelona Science Park and specialized in the discovery and development of immunotherapies for HIV infection, announces that it has entered into a clinical research collaboration with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Both companies will jointly evaluatejointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.

 

Minoryx Therapeutics and Palobiofarma receive the 2016 Biosuccess Award Blog Post

The Catalan Association of Biotechnology Companies (CataloniaBio) has recognized with the Biosuccess Award of the Year two companies associated with the Barcelona Science Park (PCB): Minoryx Therapeutics, which has just finished setting up their lab facilities at PCB, and Palobiofarma, which was based at the Parc from 2010 to 2013. The award giving ceremony was held yesterday at Palau de Pedralbes under his winter networking event CataloniaBio Gala Dinner, which this year coincided with the 10th anniversary and gathered more than 250 entrepreneurs, investors, researchers and professionals from the fields of the life sciences and health. 

 

Community Page

Community A cluster of excellence dedicated to research and innovation in life sciences The Park's community comprises 3,000 users, including research and technical personnel and entrepreneurs working for more than...

Hallmark Barcelona Science Park innovation Blog Post

2021 was a key year for companies in the life sciences sector, as is clear in the results published in the Biocat Report. A considerable number of these companies are…